PTGX - Company ID 0001377121
Protagonist Therapeutics, Inc (PTGX) reported net income of -$130.15M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$130.15M | -147.3% |
| FY 2024 | $275.19M | +448.5% |
| FY 2023 | -$78.96M | +38.0% |
| FY 2022 | -$127.39M | -1.5% |
| FY 2021 | -$125.55M | -89.8% |
| FY 2020 | -$66.15M | +14.3% |
| FY 2019 | -$77.19M | -98.3% |
| FY 2018 | -$38.92M | -5.3% |
| FY 2017 |
Protagonist Therapeutics, Inc (PTGX) reported net income of -$130.15M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2014 and fiscal 2025, Protagonist Therapeutics, Inc's net income declined from -$11.07M to -$130.15M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$36.96M |
| +0.6% |
| FY 2016 | -$37.18M | -150.2% |
| FY 2015 | -$14.86M | -34.2% |
| FY 2014 | -$11.07M | - |